Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Nationwide Decrease Seen in Cancer-Related Encounters Due to the COVID-19 Pandemic

July 29, 2020
By Hannah Slater
Article

These findings have serious implications for future cancer care and underscore the need to resume cancer care and screening.

Research published in JCO Clinical Cancer Informatics indicated that there has been a significant nationwide decrease in all cancer-related patient encounters as a result of the coronavirus disease 2019 (COVID-19) pandemic.1

The findings also inherently suggest the possibility of a future increase in patients with later-stage cancer being seen, as well as an increased demand for cancer screening procedures due to delayed tests being rescheduled.

“These findings are truly striking, as modeling from the National Cancer Institute has predicted thousands of expected increases in cancer death as a result of deferred breast and colorectal screening alone,” Karen E. Knudsen, MBA, PhD, executive vice president of Oncology Services at Jefferson Health and enterprise director of the Sidney Kimmel Cancer Center (SKCC), said in a press release.2 “This report is a nationwide call to arms, underscoring the urgent need to resume cancer screening and early detection.”

Using the TriNetX platform, researchers analyzed 20 different healthcare institutions with relevant, up-to-date encounter data from January 1, 2019 through April 30, 2020 to create the COVID and Cancer Research Network (CCRN). They then compared the data from cohorts of patients with cancer pre-COVID (January 2019 to April 2019) to current cohorts (January 2020 to April 2020). Notably, cohorts were generated for all patients with neoplasms (malignant, benign, in situ, and of unspecified behavior), with new incidence neoplasms (first encounter), with exclusively malignant neoplasms, and with new incidence malignant neoplasms.

Overall, unambiguous trends were identified which suggested a significant decline in all current cohorts evaluated, with April 2020 displaying the largest decrease in the number of patients with cancer having encounters. More specifically, among the cancer types identified, the lung, colorectal, and hematologic cancer cohorts demonstrated smaller decreases in size in April 2020 versus 2019 (-39.1%, -39.9%, -39.1%, respectively) compared with cohort size decreases for breast cancer, prostate cancer, and melanoma (-47.7%, -49.1%, -51.8%, respectively).

In addition, the investigators also found that mammograms declined 89.2% in April 2020 compared with April 2019, and colorectal cancer screenings declined by 84.5% during the same period. Moving forward, the researchers indicated that they intend to track screenings in the coming months as virus mitigation efforts are eased to help predict how many patients are continuing to delay cancer screenings due to the pandemic.

“The most significant finding in our study was the considerable drop in cancer screenings. The fact that this trend was so drastic nationwide is telling of the widespread effect of the pandemic and mitigation efforts – even in regions that had not seen a significant impact from the virus at the time,” senior author Christopher McNair, PhD, director of Cancer Informatics at SKCC, said in the release.

Throughout the summer and into the fall, the researchers will continue to observe the trends in care of patients with cancer, especially as more states become more drastically affected. According to McNair, it will be important to understand trends in cancer diagnoses to determine if delays in screening are resulting in an increased number of patients presenting with later-stage disease.

“Ultimately, these observed trends have serious implications for future cancer care and validate the need to study and monitor the effect of COVID-19 mitigation on cancer diagnosis and treatment moving forward,” the study authors wrote.

References:

1. London JW, Fazio-Eynullayeva E, Palchuk MB, Sankey P, McNair C. Effects of the COVID-19 Pandemic on Cancer-Related Patient Encounters. JCO Clinical Cancer Informatics. doi:10.1200/CCI.20.00068.

2. Nationwide Trends Show Fewer Cancer Patients Seeking Care Since Start of Pandemic [news release]. Philadelphia. Published July 27, 2020. Accessed July 28, 2020.

Recent Videos
“Developments that take high-dimensional data and come up with interpretable insights…are going to play an increasing role,” says Smita Krishnaswamy, PhD.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
Related Content
Advertisement

The new guidelines relied on trainees to bring new energy and ideas to advance the landscape of care for peritoneal surface malignancies.

New Peritoneal Surface Malignancy Guidelines Aim to Improve Unity in Oncologists

Tim Cortese
July 21st 2025
Article

The new guidelines relied on trainees to bring new energy and ideas to advance the landscape of care for peritoneal surface malignancies.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


Investigators are evaluating ZEN-3694 in combination with abemaciclib or cisplatin/etoposide across 2 clinical trials in NUT carcinoma.

ZEN-3694 Earns FDA Fast Track Designation in Metastatic NUT Carcinoma

Russ Conroy
July 16th 2025
Article

Investigators are evaluating ZEN-3694 in combination with abemaciclib or cisplatin/etoposide across 2 clinical trials in NUT carcinoma.


Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.


Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.

Pembrolizumab/Vorinostat Has Promising Activity in Squamous Cell Carcinoma

Russ Conroy
July 10th 2025
Article

Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.


Final data from the phase 3 ENLIVEN trial demonstrate long-term tumor responses and a consistent safety profile with pexidartinib.

Pexidartinib Elicits Sustained Benefit in Tenosynovial Giant Cell Tumors

Russ Conroy
July 10th 2025
Article

Final data from the phase 3 ENLIVEN trial demonstrate long-term tumor responses and a consistent safety profile with pexidartinib.

Related Content
Advertisement

The new guidelines relied on trainees to bring new energy and ideas to advance the landscape of care for peritoneal surface malignancies.

New Peritoneal Surface Malignancy Guidelines Aim to Improve Unity in Oncologists

Tim Cortese
July 21st 2025
Article

The new guidelines relied on trainees to bring new energy and ideas to advance the landscape of care for peritoneal surface malignancies.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


Investigators are evaluating ZEN-3694 in combination with abemaciclib or cisplatin/etoposide across 2 clinical trials in NUT carcinoma.

ZEN-3694 Earns FDA Fast Track Designation in Metastatic NUT Carcinoma

Russ Conroy
July 16th 2025
Article

Investigators are evaluating ZEN-3694 in combination with abemaciclib or cisplatin/etoposide across 2 clinical trials in NUT carcinoma.


Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.


Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.

Pembrolizumab/Vorinostat Has Promising Activity in Squamous Cell Carcinoma

Russ Conroy
July 10th 2025
Article

Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.


Final data from the phase 3 ENLIVEN trial demonstrate long-term tumor responses and a consistent safety profile with pexidartinib.

Pexidartinib Elicits Sustained Benefit in Tenosynovial Giant Cell Tumors

Russ Conroy
July 10th 2025
Article

Final data from the phase 3 ENLIVEN trial demonstrate long-term tumor responses and a consistent safety profile with pexidartinib.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.